Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots

M Bosilkovska, C F Samer, J Déglon, M Rebsamen, C Staub, P Dayer, B Walder, J A Desmeules, Y Daali, M Bosilkovska, C F Samer, J Déglon, M Rebsamen, C Staub, P Dayer, B Walder, J A Desmeules, Y Daali

Abstract

The suitability of the capillary dried blood spot (DBS) sampling method was assessed for simultaneous phenotyping of cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) using a cocktail approach. Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A), and fexofenadine (P-gp) with coffee/Coke (CYP1A2) on four occasions. They received the cocktail alone (session 1), and with the CYP inhibitors fluvoxamine and voriconazole (session 2) and quinidine (session 3). In session 4, subjects received the cocktail after a 7-day pretreatment with the inducer rifampicin. The concentrations of probes/metabolites were determined in DBS and plasma using a single liquid chromatography-tandem mass spectrometry method. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. Important modulation of CYP and P-gp activities was observed in the presence of inhibitors and the inducer. Minimally invasive one- and three-point (at 2, 3, and 6 h) DBS-sampling methods were found to reliably reflect CYP and P-gp activities at each session.

Trial registration: ClinicalTrials.gov NCT01731067.

Figures

Figure 1
Figure 1
Concentration–time profiles for CYP probe substrates (circles) and their metabolites (triangles) obtained in 10 µl of capillary DBS (dashed lines) and venous plasma samples (continuous lines) after oral administration of cocktail alone (left column), in the presence of inhibitor(s) (middle), or in the presence of an inducer (right) in 10 healthy volunteers. CYP1A2 profile is presented only for volunteers who received coffee (n = 6); CYP2D6 profiles are presented only for EMs and UMs (n = 7). Error bars represent SD. CYP, cytochrome P450; DBS, dried blood spot; EM, extensive metabolizer; UM, ultrarapid metabolizer.
Figure 2
Figure 2
Concentration–time profile of fexofenadine in capillary DBS (dashed lines) and venous plasma samples (continuous lines) after administration of the cocktail capsule alone (circles), with a P-gp inhibitor (squares), or with a P-gp inducer (triangles) in 10 healthy volunteers. Error bars represent SD. DBS, dried blood spot; P-gp, P-glycoprotein.
Figure 3
Figure 3
Metabolic ratio profiles after oral administration of cocktail capsule alone (diamonds), with an inhibitor (squares), or with an inducer (triangles) in dried blood spots. *P < 0.05; **P < 0.01. dor/dem: continuous lines are used for extensive metabolizers (EMs) and dashed lines for intermediate metabolizers (IMs). bup, bupropion; caf, caffeine; dem, dextromethorphan; dor, dextrorphan; mdz, midazolam; OH-bup, 4-hydroxybupropion; OH-flb, 4-hydroxyflurbiprofen; flb, flurbiprofen; OH-mdz, 1-hydroxymidazolam; OH-opz, 5-hydroxyomeprazole; opz, omeprazole; par, paraxanthine.

References

    1. Konig J., Muller F., Fromm M.F. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65:944–966.
    1. Chainuvati S., et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”. Clin. Pharmacol. Ther. 2003;74:437–447.
    1. Ryu J.Y., et al. Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther. 2007;82:531–540.
    1. Turpault S., et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol. 2009;68:928–935.
    1. Christensen M., et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin. Pharmacol. Ther. 2003;73:517–528.
    1. Zgheib N.K., Frye R.F., Tracy T.S., Romkes M., Branch R.A. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin. Pharmacol. Ther. 2006;80:257–263.
    1. Dumond J.B., et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin. Pharmacol. Ther. 2010;87:735–742.
    1. Pedersen R.S., Damkier P., Christensen M.M., Brosen K. A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. Eur. J. Clin. Pharmacol. 2013;69:1997–1999.
    1. Déglon J., Lauer E., Thomas A., Mangin P., Staub C. Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis. Anal. Bioanal. Chem. 2010;396:2523–2532.
    1. Patel P., et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br. J. Clin. Pharmacol. 2013;75:805–813.
    1. van der Elst K.C., et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob. Agents Chemother. 2013;57:4999–5004.
    1. Daali Y., et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin. Pharmacol. Ther. 2012;91:489–496.
    1. de Boer T., et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed. Chromatogr. 2011;25:1112–1123.
    1. Ullmann A.J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opin. 2003;19:263–271.
    1. Bosilkovska M., et al. Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. Bioanalysis. 2014;6:151–164.
    1. Fuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin. Pharmacol. Ther. 2007;81:270–283.
    1. Emmons G., Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis. 2010;2:1791–1796.
    1. Culm-Merdek K.E., von Moltke L.L., Harmatz J.S., Greenblatt D.J. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. Br. J. Clin. Pharmacol. 2005;60:486–493.
    1. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.E., Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996;51:73–78.
    1. Kanebratt K.P., et al. Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin. Pharmacol. Ther. 2008;84:589–594.
    1. Backman J.T., Granfors M.T., Neuvonen P.J. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur. J. Clin. Pharmacol. 2006;62:451–461.
    1. Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 2009;10:730–753.
    1. Loboz K.K., et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin. Pharmacol. Ther. 2006;80:75–84.
    1. Palovaara S., Pelkonen O., Uusitalo J., Lundgren S., Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 2003;74:326–333.
    1. European Medicines Agency Guideline on the Investigation of Drug Interactions . < > ( 2012
    1. Liu P., Foster G., LaBadie R.R., Gutierrez M.J., Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol. 2008;48:73–84.
    1. Zgheib N.K., Frye R.F., Tracy T.S., Romkes M., Branch R.A. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br. J. Clin. Pharmacol. 2007;63:477–487.
    1. Inui N., et al. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. Clin. Pharmacol. Ther. 2013;94:702–708.
    1. Niioka T., Uno T., Sugimoto K., Sugawara K., Hayakari M., Tateishi T. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur. J. Clin. Pharmacol. 2007;63:1031–1038.
    1. Frank D., Jaehde U., Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 2007;63:321–333.
    1. Borges S., Li L., Hamman M.A., Jones D.R., Hall S.D., Gorski J.C. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab. Dispos. 2005;33:1052–1055.
    1. Tamminga W.J., et al. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur. J. Clin. Pharmacol. 2001;57:143–146.
    1. Chaobal H.N., Kharasch E.D. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther. 2005;78:529–539.
    1. Eap C.B., et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur. J. Clin. Pharmacol. 2004;60:237–246.
    1. Saari T.I., Laine K., Leino K., Valtonen M., Neuvonen P.J., Olkkola K.T. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin. Pharmacol. Ther. 2006;79:362–370.
    1. Backman J.T., Kivistö K.T., Olkkola K.T., Neuvonen P.J. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. 1998;54:53–58.
    1. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., Hall S.D. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 2001;69:114–121.
    1. US Food and Drug Administration. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations .< > ( 2012
    1. Kirchheiner J., et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13:619–626.
    1. Lasker J.M., Wester M.R., Aramsombatdee E., Raucy J.L. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys. 1998;353:16–28.
    1. Streetman D.S., Bertino J.S., Jr, Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187–216.
    1. Bosilkovska M., Clément M., Dayer P., Desmeules J., Daali Y. Incorporation of flurbiprofen in a 4-drug cytochrome P450 phenotyping cocktail. Basic Clin. Pharmacol. Toxicol. 2014.
    1. Croft M., Keely B., Morris I., Tann L., Lappin G. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet. 2012.
    1. Takahata T., Yasui-Furukori N., Yoshiya G., Uno T., Sugawara K., Tateishi T. Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates. Basic Clin. Pharmacol. Toxicol. 2004;94:252–256.
    1. Jefferson J.W., Pradko J.F., Muir K.T. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther. 2005;27:1685–1695.
    1. Kotlyar M., et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol. 2005;25:226–229.
    1. Reese M.J., Wurm R.M., Muir K.T., Generaux G.T., St John-Williams L., McConn D.J. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab. Dispos. 2008;36:1198–1201.
    1. Hesse L.M., Greenblatt D.J., von Moltke L.L., Court M.H. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol. 2006;46:567–576.
    1. Rebsamen M.C., et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;9:34–41.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere